The clinical evaluation of the effectiveness of various minimally invasive methods in the treatment of central serous chorioretinopathy
DOI:
https://doi.org/10.31288/oftalmolzh202523441Keywords:
central serous chorioretinopathy, leakage point, subthreshold micropulse laser therapy, optical coherence tomography, fluorescent angiographyAbstract
Aim: clinical evaluation of the effectiveness of various lasers in treating acute and chronic central serous chorioretinopathy.
Methods. The study involved 50 patients (53 eyes) with central serous chorioretinopathy (CSCR): 32 (60.4%) with the acute form and 18 (39.6%) with the chronic form. Patients were divided into three groups based on treatment and the leakage point's (LP) location. Group 1; 19 patients (19 eyes) received focal laser coagulation. Group 2 included 24 patients (24 eyes) who underwent subthreshold micropulse laser treatment (SMLT) for retinal neuroepithelial detachment. Group 3; 7 patients (10 eyes) with chronic disease underwent focal coagulation combined with SMLT, with LP confirmed via fluorescein angiography (FA). The observation lasted 6 months.
Results. At the 4-week follow-up, Group 1's best corrected visual acuity (BCVA) improved by 60.2% to 0.75±0.01, with central retinal thickness (CRT) decreasing by 72.8% to 257.2±13.1 µm (p<0.05). Group 2 experienced a 30% BCVA improvement to 0.5±0.02, and a 32.1% CRT reduction to 266.6±10.3 µm (p<0.05). Group 3 showed a 26.5% BCVA increase to 0.35±0.01, with CRT decreasing by 27.3% to 280.6±14.5 µm (p<0.05).
Conclusions. When the leakage point (LP) is located in the subfoveal region, in cases of the chronic form of the disease with large-area diffuse hyperfluorescence, in situations where the filtration point is not detected by fluorescein angiography (FA), and in cases of disease recurrence, subthreshold micropulse laser treatment, the use of subthreshold micropulse mode laser devices with a yellow wavelength (577 nm) is considered a safe and effective therapeutic method.
References
Gawecki M, Jaszczuk-Maciejewska A, Jurska-Jasko A, Kneba M, Grzybowski A. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019;19:160. https://doi.org/10.1186/s12886-019-1171-5
Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F, et al. Central serous chorioretinopathy: pathogenesis and management. Clin Ophthalmol. 2019;13:2341-52. https://doi.org/10.2147/OPTH.S220845
Gawecki M, Jaszczuk A, Grzybowski A. Short-term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function. J Clin Med. 2020;9(11):3429. https://doi.org/10.3390/jcm9113429
Chhablani J. Subthreshold laser therapy guidelines for retinal diseases. Eye (Lond). 2022;36:2234-5. https://doi.org/10.1038/s41433-022-02136-w
Feenstra HMA, van Dijk EHC, Cheung CMG, Ohno-Matsui K, Lai TYY, Koizumi H, et al. Central serous chorioretinopathy: an evidence-based treatment guideline. Prog Retin Eye Res. 2024;101:101236. https://doi.org/10.1016/j.preteyeres.2024.101236
Arora S, Sridharan P, Arora T, Chhabra M, Ghosh B. Subthreshold diode micropulse laser versus observation in acute central serous chorioretinopathy. Clin Exp Optom. 2019;102:79-85. https://doi.org/10.1111/cxo.12818
Gaw˛ecki M, Jaszczuk-Maciejewska A, Jurska-Ja'sko A, Kneba M, Grzybowski A. Transfoveal micropulse laser treatment of central serous chorioretinopathy within six months of disease onset. J Clin Med. 2019;8(9):1398. https://doi.org/10.3390/jcm8091398
Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27:1339-46. https://doi.org/10.1038/eye.2013.236
Lim JW, Kang SW, Kim YT. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol. 2011;95:514-7. https://doi.org/10.1136/bjo.2010.182121
Ober MD, Yannuzzi LA, Do DV, et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology. 2005;112:2088-94. https://doi.org/10.1055/a-1531-5605
Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30:1698-703. https://doi.org/10.1097/IAE.0b013e3181da4354
Lai TY, Chan WM, Li H. Safety-enhanced photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: a short-term pilot study. Br J Ophthalmol. 2006;90:869-74. https://doi.org/10.1136/bjo.2006.090282
Klatt C, Elsner H, Porksen E, et al. Selective retina therapy in central serous chorioretinopathy with a detachment of the pigmentary epithelium. Ophthalmology. 2006;103:850-5. https://doi.org/10.1007/s00347-006-1415-7
Bodea F, Bungau SG, Bogdan MA, Vesa CM, Radu A, Tarce AG, et al. Micropulse laser therapy as an integral part of eye disease management. Medicina (B Aires). 2023;59(8):1388. https://doi.org/10.3390/medicina59081388
Uzlu D, Erdol H, Kola M, Ozbay AD. The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy. Lasers Med Sci. 2021;36:981-8. https://doi.org/10.1007/s10103-020-03129-5
Wang M, Munch IC, Hasler PW, Prunte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008;86:126-45. https://doi.org/10.1111/j.1600-0420.2007.00889.x
Wang MS, Sander B, Larsen M. Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2002;133(6):787-93. https://doi.org/10.1016/S0002-9394(02)01438-1
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Yusupov A. F., Karimova M. Kh., Djamalova Sh. A., Ibodullayeva D. CH., Aktamov A. SH.
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
.png)
